News

Article

Mirtazapine Tablets Recalled

Aurobindo Pharma USA, Inc. voluntarily recalled Mirtazapine Tablets due to an error on the label that listed the incorrect strength.

Aurobindo Pharma USA, Inc. announced on Dec. 30, 2019 that it was voluntarily recalling on lot of Mirtazapine tablets because the label on the bottles incorrectly stated the strength as Mirtazapine 7.5 mg, but the product may contain 15 mg tablets. Mirtazapine tablets are used to treat major depressive disorder. The company stated in a press release that taking a higher dose may increase risks such as sedation, agitation, increased reflexes, tremor, and gastrointestinal distress, among other symptoms.

The recalled lot, 03119002A3, has an expiration date of 03/2022 and is packaged in 500-count bottles. Adverse events may be reported to FDA through its MedWatch program.

Source: FDA

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content